Published in Scientifica (Cairo) on June 12, 2014
Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation (2003) 3.68
The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci U S A (1997) 3.23
Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation (2001) 3.12
A novel site-targeted ultrasonic contrast agent with broad biomedical application. Circulation (1996) 2.72
Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res (2003) 2.70
19F magnetic resonance imaging for stem/progenitor cell tracking with multiple unique perfluorocarbon nanobeacons. FASEB J (2007) 2.63
Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol (2012) 2.56
Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol (2006) 2.45
Molecular MR imaging of melanoma angiogenesis with alphanubeta3-targeted paramagnetic nanoparticles. Magn Reson Med (2005) 2.30
Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation (2004) 2.30
Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis. JACC Cardiovasc Imaging (2008) 2.14
Structure of human methionine aminopeptidase-2 complexed with fumagillin. Science (1998) 1.94
Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRI. Magn Reson Med (2004) 1.83
Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth. J Clin Invest (2009) 1.78
Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis. Circulation (2002) 1.77
Angiogenesis-dependent and independent phases of intimal hyperplasia. Circulation (2004) 1.71
Quantitative "magnetic resonance immunohistochemistry" with ligand-targeted (19)F nanoparticles. Magn Reson Med (2004) 1.68
Minute dosages of alpha(nu)beta3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits. FASEB J (2008) 1.67
Angiogenesis in human coronary atherosclerotic plaques. Am J Pathol (1994) 1.65
Imaging of Vx-2 rabbit tumors with alpha(nu)beta3-integrin-targeted 111In nanoparticles. Int J Cancer (2007) 1.57
Properties of an entropy-based signal receiver with an application to ultrasonic molecular imaging. J Acoust Soc Am (2007) 1.54
Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2. Proc Natl Acad Sci U S A (1998) 1.51
Synthesis and characterization of stable fluorocarbon nanostructures as drug delivery vehicles for cytolytic peptides. Nano Lett (2008) 1.47
Molecular imaging and therapy of atherosclerosis with targeted nanoparticles. J Magn Reson Imaging (2007) 1.46
Magnetic resonance contrast enhancement of neovasculature with alpha(v)beta(3)-targeted nanoparticles. Magn Reson Med (2000) 1.44
Perfluorocarbon nanoemulsions for quantitative molecular imaging and targeted therapeutics. Ann Biomed Eng (2009) 1.39
Improved molecular imaging contrast agent for detection of human thrombus. Magn Reson Med (2003) 1.37
In vitro demonstration using 19F magnetic resonance to augment molecular imaging with paramagnetic perfluorocarbon nanoparticles at 1.5 Tesla. Invest Radiol (2006) 1.29
Functional anatomy and hemodynamic characteristics of vasa vasorum in the walls of porcine coronary arteries. Anat Rec A Discov Mol Cell Evol Biol (2003) 1.27
Targeted PARACEST nanoparticle contrast agent for the detection of fibrin. Magn Reson Med (2006) 1.25
Hypercholesterolemia inhibits angiogenesis in response to hindlimb ischemia: nitric oxide-dependent mechanism. Circulation (2000) 1.25
Molecular imaging of human thrombus with computed tomography. Acad Radiol (2005) 1.21
Hypercholesterolemia attenuates angiogenesis but does not preclude augmentation by angiogenic cytokines. Circulation (1997) 1.21
Pharmacokinetics and side effects of perfluorocarbon-based blood substitutes. Artif Cells Blood Substit Immobil Biotechnol (1994) 1.20
Nanoparticle pharmacokinetic profiling in vivo using magnetic resonance imaging. Magn Reson Med (2008) 1.19
Theragnostics for tumor and plaque angiogenesis with perfluorocarbon nanoemulsions. Angiogenesis (2010) 1.17
A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. J Natl Compr Canc Netw (2011) 1.16
High sensitivity: high-resolution SPECT-CT/MR molecular imaging of angiogenesis in the Vx2 model. Invest Radiol (2009) 1.15
Characterization of digital waveforms using thermodynamic analogs: detection of contrast-targeted tissue in vivo. IEEE Trans Ultrason Ferroelectr Freq Control (2006) 1.14
Nanomedicine opportunities for cardiovascular disease with perfluorocarbon nanoparticles. Nanomedicine (Lond) (2006) 1.13
Alphavbeta3-targeted nanotherapy suppresses inflammatory arthritis in mice. FASEB J (2009) 1.13
Nanomedicine: perspective and promises with ligand-directed molecular imaging. Eur J Radiol (2009) 1.13
Clinical applications of perfluorocarbon nanoparticles for molecular imaging and targeted therapeutics. Int J Nanomedicine (2007) 1.09
Gadolinium-modulated 19F signals from perfluorocarbon nanoparticles as a new strategy for molecular imaging. Magn Reson Med (2008) 1.09
Current and emerging targeted therapies for metastatic breast cancer. Cancer (2011) 1.08
Fibrin-targeted perfluorocarbon nanoparticles for targeted thrombolysis. Nanomedicine (Lond) (2007) 1.08
Intramural delivery of rapamycin with alphavbeta3-targeted paramagnetic nanoparticles inhibits stenosis after balloon injury. Arterioscler Thromb Vasc Biol (2008) 1.07
Post-formulation peptide drug loading of nanostructures for metered control of NF-κB signaling. Biomaterials (2011) 1.04
Emerging nanomedicine opportunities with perfluorocarbon nanoparticles. Expert Rev Med Devices (2007) 1.02
Mechanisms of nucleotide trafficking during siRNA delivery to endothelial cells using perfluorocarbon nanoemulsions. Biomaterials (2010) 1.02
Simultaneous dual frequency 1H and 19F open coil imaging of arthritic rabbit knee at 3T. IEEE Trans Med Imaging (2010) 1.02
Neovascularization in atherectomy specimens from patients with unstable angina: implications for pathogenesis of unstable angina. Am Heart J (1998) 1.01
Quantitative magnetic resonance fluorine imaging: today and tomorrow. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2010) 1.00
Molecular imaging with targeted perfluorocarbon nanoparticles: quantification of the concentration dependence of contrast enhancement for binding to sparse cellular epitopes. Ultrasound Med Biol (2007) 1.00
Cardiovascular disease in the JCR:LA-cp rat. Mol Cell Biochem (1998) 1.00
Nanomedicine strategies for molecular targets with MRI and optical imaging. Future Med Chem (2010) 0.99
Molecular imaging by MRI. Curr Cardiol Rep (2006) 0.97
Molecular MR imaging of neovascular progression in the Vx2 tumor with αvβ3-targeted paramagnetic nanoparticles. Radiology (2013) 0.97
Anti-angiogenic perfluorocarbon nanoparticles for diagnosis and treatment of atherosclerosis. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2010) 0.96
Targeting of alpha(nu)beta(3)-integrins expressed on tumor tissue and neovasculature using fluorescent small molecules and nanoparticles. Nanomedicine (Lond) (2010) 0.95
The potential role of perfluorochemicals (PFCs) in diagnostic imaging. Artif Cells Blood Substit Immobil Biotechnol (1994) 0.95
Synergistic effect of antiangiogenic nanotherapy combined with methotrexate in the treatment of experimental inflammatory arthritis. Nanomedicine (Lond) (2010) 0.94
Angiogenesis imaging with vascular-constrained particles: the why and how. Eur J Nucl Med Mol Imaging (2010) 0.91
MR angiogenesis imaging with Robo4- vs. alphaVbeta3-targeted nanoparticles in a B16/F10 mouse melanoma model. FASEB J (2010) 0.91
Detection and quantification of angiogenesis in experimental valve disease with integrin-targeted nanoparticles and 19-fluorine MRI/MRS. J Cardiovasc Magn Reson (2008) 0.90
High-frequency ultrasonic detection of thrombi with a targeted contrast system. Ultrasound Med Biol (1997) 0.90
Glucose tolerance and insulin resistance in the JCR:LA-corpulent rat: effect of miglitol (Bay m1099). Metabolism (1999) 0.90
Renal vascular inflammation induced by Western diet in ApoE-null mice quantified by (19)F NMR of VCAM-1 targeted nanobeacons. Nanomedicine (2009) 0.90
Plasma lipid secretion and clearance in hyperlipidemic JCR:LA-corpulent rats. Arteriosclerosis (1990) 0.90
Molecular imaging of angiogenic therapy in peripheral vascular disease with alphanubeta3-integrin-targeted nanoparticles. Magn Reson Med (2010) 0.90
Detection of targeted perfluorocarbon nanoparticle binding using 19F diffusion weighted MR spectroscopy. Magn Reson Med (2008) 0.89
MR three-dimensional molecular imaging of intramural biomarkers with targeted nanoparticles. J Cardiovasc Magn Reson (2006) 0.87
Targeted magnetic resonance imaging contrast agents. Methods Mol Med (2006) 0.86
Rationale for a nanomedicine approach to thrombolytic therapy. Stroke (2010) 0.84
Assessment of tumor angiogenesis: dynamic contrast-enhanced MRI with paramagnetic nanoparticles compared with Gd-DTPA in a rabbit Vx-2 tumor model. Contrast Media Mol Imaging (2010) 0.84
Quantitative cardiovascular magnetic resonance for molecular imaging. J Cardiovasc Magn Reson (2010) 0.84
Quantification of water exchange kinetics for targeted PARACEST perfluorocarbon nanoparticles. NMR Biomed (2011) 0.83
Magnetic resonance nanoparticles for cardiovascular molecular imaging and therapy. Expert Rev Cardiovasc Ther (2005) 0.82
MR molecular imaging of aortic angiogenesis. JACC Cardiovasc Imaging (2010) 0.82
Rapid quantification of oxygen tension in blood flow with a fluorine nanoparticle reporter and a novel blood flow-enhanced-saturation-recovery sequence. Magn Reson Med (2012) 0.81
Magnetic resonance chemical exchange saturation transfer imaging and nanotechnology. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2012) 0.80
Decreased serum lipids, serum insulin and triacylglycerol synthesis in adipose tissue of JCR:LA-corpulent rats treated with benfluorex. Biochim Biophys Acta (1991) 0.80
Antiatherogenic effects of long-term benfluorex treatment in male insulin resistant JCR:LA-cp rats. Atherosclerosis (1997) 0.79
Effects of benfluorex on serum triacylglycerols and insulin sensitivity in the corpulent rat. Can J Physiol Pharmacol (1996) 0.78
Independence of myocardial disease in the JCR:LA-corpulent rat on plasma cholesterol concentration. Clin Invest Med (1991) 0.78
Perfluorocarbon nanoparticles for physiological and molecular imaging and therapy. Adv Chronic Kidney Dis (2013) 0.77